Senzime AB (publ) (SEZI.ST)
Stockholm · SEK · Healthcare · Medical Devices
SEK 2.83 (+2.73%) as of
Key statistics
- Market cap
- 444.13M
- Forward P/E
- -9.42
- EPS (TTM)
- -0.7100
- Dividend yield
- 0.00%
- 52-week range
- 2.3500 – 6.2400
- Beta
- 0.43
- Revenue (TTM)
- 102.73M
- Profit margin
- -109.30%
- Analyst target
- SEK 10.50
- Volume
- 417.06k
About Senzime AB (publ)
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue's opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz Analyzer and OnZurf Probe. The company has a strategic connectivity and licensing agreement with Masimo that grants Senzime the rights to use some of Masimo's intellectual property; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system. Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Uppsala, Sweden
- Employees
- 59
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.